Metagelan

Metamizole Sodium Monohydrate, the active ingredient in Metagelan, is a pyrazolone analgesic presented as an oral dosage form for oral use. It provides analgesic and antipyretic effects for the treatment of pain and fever in adults.

GNH USA supplies Metagelan as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metamizole Sodium Monohydrate is employed for pain and fever management by inhibiting prostaglandin synthesis pathways.

- Pain: reduces moderate to severe acute pain. - Fever: lowers elevated body temperature in febrile states. - Postoperative pain: alleviates discomfort following surgical procedures. - Colic: eases visceral pain associated with gastrointestinal colic.

Metagelan may cause a range of adverse reactions, most of which are dose‑related and reversible.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Dizziness: transient light‑headedness. - Skin rash: erythematous or maculopapular eruptions. - Elevated liver enzymes: transient hepatic enzyme rise.

Serious or Rare Side Effects: - Agranulocytosis: severe reduction in white blood cells, requiring immediate medical attention. - Anaphylactic reaction: rapid onset of airway swelling, hypotension, and urticaria.

Metagelan should be used with caution in specific patient populations and clinical situations.

- Renal impairment: assess kidney function before initiating therapy. - Hepatic disease: monitor liver enzymes during treatment. - Hematologic disorders: avoid in patients with a history of agranulocytosis. - Concomitant NSAIDs: increase risk of gastrointestinal bleeding. - Pregnancy and breastfeeding: use only if the potential benefit justifies the potential risk. - Store at ambient temperature: keep below 25°C, in the original packaging, protected from moisture and direct sunlight.

Metagelan can interact with several medicines, altering efficacy or safety.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): heightened bleeding risk. - Immunosuppressants (e.g., azathioprine): may exacerbate bone‑marrow suppression.

Moderate Interactions (Monitor Closely): - Other NSAIDs or COX inhibitors: additive gastrointestinal toxicity. - Diuretics: possible reduction in renal clearance. - Lithium: increased lithium levels may occur. - Methotrexate: enhanced toxicity risk.